CX-904 is under clinical development by CytomX Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CX-904’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CX-904 overview

CX-904 is under development for the treatment of solid tumors and colorectal cancer. The drug candidate is a T-cell engaging bi-specific antibody that acts by targeting both cluster of differentiation (CD3) and epidermal growth factor receptor (EGFR). It is developed based on probody platform which is designed to localize antibody binding to a diseased tissue.

CytomX Therapeutics overview

Cytomx Therapeutics (Cytomx) is a clinical-stage biopharmaceutical company. it develops novel therapeutic antibodies and Probody therapeutics for the treatment of cancer. The company’s leading product candidates include CX-072, CX-2009, BMS-986249, CX-2029, CX-188, pro body drug conjugate, and T-cell bispecific. Its products CX-072, is a PD-L1 targeting Probody therapeutic for the treatment of cancer; CX-2009, currently under is a CD166-directed PDC for the treatment of cancer; BMS-986249, under Phase is a CTLA-4-directed Probody therapeutic intended for the treatment of solid cancers; CX-2029, under is a PDC directed against CD71 intended for the treatment of B-cell lymphoma; CX-188, is a PD-1-targeting Probody therapeutic. The company also carries out various phases of clinical trails. Cytomx is headquartered in South San Francisco, California, the US.

For a complete picture of CX-904’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.